Correlation between betatrophin/angiogenin-likeprotein3/lipoprotein lipase pathway and severity of coronary artery disease in Kazakh patients with coronary heart disease

Table 1 Comparison of general baseline data between Kazakh and Han patients with coronary heart disease

Variables	Kazakh			Han
	CHD (n = 79)	Non-CHD (n = 72)	P value	CHD (n = 61)	Non-CHD (n = 65)	P value
Age (yr)	52.27 ± 12.10	53.77 ± 12.24	0.16	53.78 ± 13.56	52.63 ± 11.73	0.14
SBP (mmHg)	135.13 ± 15.46	129.24 ± 13.42	0.27	129.44 ± 15.69	125.58 ± 16.81	0.24
DBP (mmHg)	84.85 ± 13.21	81.34 ± 12.52	0.18	81.41 ± 16.39	79.26 ± 12.14	0.15
BMI	27.43 ± 2.97 1,3	24.76 ± 3.22	0.007	26.74 ± 2.432	24.22 ± 3.37	0.03
GLU (mmol/L)	5.53 ± 0.62	54.06 ± 14.16	0.26	5.16 ± 0.37	4.73 ± 0.52	0.24
Fructosamine (μmol/L)	241.82 ± 23.42	235.89 ± 18.54	0.33	246.02 ± 21.42	239.71 ± 18.25	0.13
HOMA-IR	0.95 ± 0.11	0.93 ± 0.09	0.13	0.89 ± 0.06	0.87 ± 0.07	0.09
HOMA-β	0.81 ± 0.06	0.80 ± 0.09	0.15	0.78 ± 0.14	0.79 ± 0.07	0.11
TC (mmol/L)	5.37 ± 0.731,3	4.28 ± 0.34	0.005	5.01 ± 1.092	4.12 ± 0.76	0.004
TG (mmol/L)	1.36 ± 0.601,3	1.14 ± 0.56	0.007	1.15 ± 0.652	1.08 ± 0.37	0.006
LDL-C (mmol/L)	3.15 ± 0.621,3	2.56 ± 0.44	0.004	2.98 ± 1.022	2.87 ± 0.56	0.02
HDL-C (mmol/L)	1.85 ± 0.39	1.93 ± 0.2 3	0.21	1.87 ± 0.38	2.01 ± 0.36	0.26

¹Comparison between Kazakh CHD patients and control group patients (P < 0.01).

²Comparison between Han CHD patients and control group patients (P < 0.05).

³Comparison between Kazakh and Han patients (P <0.01).

CHD: Coronary heart disease; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; BMI: Body mass index; GLU: Glucose; HOMA-IR: Homeostasis model assessment-insulin resistance; HOMA-β: Homeostasis model assessment-β cells; TC: Total cholesterol; TG: Triglycerides; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High-density lipoprotein cholesterol.